Login Register Cart 0
Generic placeholder image

Letters in Organic Chemistry

Editor-in-Chief

ISSN (Print): 1570-1786
ISSN (Online): 1875-6255

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Synthesis, Bioactivity Evaluation, and Molecular Docking Study of Tranilast Analogs as Anticancer Agents

Author(s): Phuong-Thuy T. Phan, Tuan-Anh N. Pham*, Ngoc Phuong Nguyen, Van-Anh Tran Nguyen and Tuyet Hong Nguyen

Volume 21, Issue 3, 2024

Published on: 20 October, 2023

Page: [271 - 278] Pages: 8

DOI: 10.2174/0115701786268073230926160649

Price: $65

Abstract

Developing new agents with higher therapeutic potential and less toxicity to overcome the limitations of chemotherapy in cancer treatment has been identified as an urgent need and priority. Recent studies have shown promising anticancer activities of tranilast when used alone or in combination with other chemotherapeutic agents. This research aims to synthesize tranilast analogs, evaluate in vitro anticancer activity, and dock into the TGFβ1 target to find stronger anticancer agents. Tranilast (5a) and analogs (5b–f) were synthesized from anthranilic acid derivatives, Meldrum’s acid, and benzaldehydes based on the Knoevenagel-Doebner reaction. The compounds were evaluated for in vitro cytotoxicity activity by MTT assay and docked into the TGFβ1 target using AutoDockTools–1.5.6. Tranilast (5a) and seven analogs (5b–h) were successfully synthesized and analyzed for their structures. Four analogs (5b–d, 5f) possessed stronger effects on both HepG2 and MCF-7 cell lines with proliferation inhibitions at concentrations of 100 μg/mL in the range of 41 to 95% compared to tranilast (16.95% and 22.64%). Compound 5f exhibited the most potent analog with IC50 = 27.57 μg/mL (HepG2) and 16.67 μg/mL (MCF-7) compared to tranilast (IC50 > 100 μg/mL) and had good binding affinity on TGFβ1 target (docking score ˗7.35 Kcal/mol). Four of seven tranilast analogs possessed stronger cytotoxicity activity on both HepG2 and MCF-7 cell lines compared to that of the parent compound, tranilast. Notably, compound 5f displayed the most potent activity and good binding affinity on the TGFβ1 target, indicating the potential for further study as an anticancer agent.

« Previous Next »
Graphical Abstract

[1]
Bray, F.; Laversanne, M.; Weiderpass, E.; Soerjomataram, I. Cancer, 2021, 127(16), 3029-3030.
[http://dx.doi.org/10.1002/cncr.33587] [PMID: 34086348]
[2]
Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. CA Cancer J. Clin., 2021, 71(3), 209-249.
[http://dx.doi.org/10.3322/caac.21660] [PMID: 33538338]
[3]
Xia, C.; Dong, X.; Li, H.; Cao, M.; Sun, D.; He, S.; Yang, F.; Yan, X.; Zhang, S.; Li, N.; Chen, W. Chin. Med. J., 2022, 135(5), 584-590.
[http://dx.doi.org/10.1097/CM9.0000000000002108] [PMID: 35143424]
[4]
Keefe, D.M.K.; Bateman, E.H. J. Natl. Cancer Inst. Monogr., 2019, 2019(53), lgz008.
[http://dx.doi.org/10.1093/jncimonographs/lgz008] [PMID: 31425592]
[5]
Alnasser, S.M. Gene, 2022, 840, 146748.
[http://dx.doi.org/10.1016/j.gene.2022.146748] [PMID: 35868413]
[6]
Montaño-Samaniego, M.; Bravo-Estupiñan, D.M.; Méndez-Guerrero, O.; Alarcón-Hernández, E.; Ibáñez-Hernández, M. Front. Oncol., 2020, 10, 605380.
[http://dx.doi.org/10.3389/fonc.2020.605380] [PMID: 33381459]
[7]
Waldman, A.D.; Fritz, J.M.; Lenardo, M.J. Nat. Rev. Immunol., 2020, 20(11), 651-668.
[http://dx.doi.org/10.1038/s41577-020-0306-5] [PMID: 32433532]
[8]
Debela, D.T.; Muzazu, S.G.Y.; Heraro, K.D.; Ndalama, M.T.; Mesele, B.W.; Haile, D.C.; Kitui, S.K.; Manyazewal, T. SAGE Open Med., 2021, 9.
[http://dx.doi.org/10.1177/20503121211034366] [PMID: 34408877]
[9]
Anand, U.; Dey, A.; Chandel, A.K.S.; Sanyal, R.; Mishra, A.; Pandey, D.K.; De Falco, V.; Upadhyay, A.; Kandimalla, R.; Chaudhary, A.; Dhanjal, J.K.; Dewanjee, S.; Vallamkondu, J.; Pérez de la Lastra, J.M. Genes Dis., 2023, 10(4), 1367-1401.
[http://dx.doi.org/10.1016/j.gendis.2022.02.007] [PMID: 37397557]
[10]
Liu, S.; Khan, A.R.; Yang, X.; Dong, B.; Ji, J.; Zhai, G. J. Control. Release, 2021, 335, 1-20.
[http://dx.doi.org/10.1016/j.jconrel.2021.05.012] [PMID: 33991600]
[11]
Elmore, L.W.; Greer, S.F.; Daniels, E.C.; Saxe, C.C.; Melner, M.H.; Krawiec, G.M.; Cance, W.G.; Phelps, W.C. CA Cancer J. Clin., 2021, 71(2), 107-139.
[http://dx.doi.org/10.3322/caac.21652] [PMID: 33326126]
[12]
Zhang, Z.; Zhou, L.; Xie, N.; Nice, E.C.; Zhang, T.; Cui, Y.; Huang, C. Signal Transduct. Target. Ther., 2020, 5(1), 113.
[http://dx.doi.org/10.1038/s41392-020-00213-8] [PMID: 32616710]
[13]
Komatsu, H.; Kojima, M.; Tsutsumi, N.; Hamano, S.; Kusama, H.; Ujiie, A.; Ikeda, S.; Nakazawa, M. Jpn. J. Pharmacol., 1988, 46(1), 43-51.
[http://dx.doi.org/10.1016/S0021-5198(19)43349-0] [PMID: 2452912]
[14]
Saito, H.; Fushida, S.; Harada, S.; Miyashita, T.; Oyama, K.; Yamaguchi, T.; Tsukada, T.; Kinoshita, J.; Tajima, H.; Ninomiya, I.; Ohta, T. Gastric Cancer, 2018, 21(1), 55-67.
[http://dx.doi.org/10.1007/s10120-017-0726-5] [PMID: 28540637]
[15]
Nakashima, T.; Nagano, S.; Setoguchi, T.; Sasaki, H.; Saitoh, Y.; Maeda, S.; Komiya, S.; Taniguchi, N. Oncol. Rep., 2019, 42(1), 176-188.
[http://dx.doi.org/10.3892/or.2019.7150] [PMID: 31059083]
[16]
Hashemzehi, M.; Yavari, N.; Rahmani, F.; Asgharzadeh, F.; Soleimani, A.; Shakour, N.; Avan, A.; Hadizadeh, F.; Fakhraie, M.; Marjaneh, R.M.; Ferns, G.A.; Reisi, P.; Ryzhikov, M.; Khazaei, M.; Hassanian, S.M. EXCLI J., 2021, 20, 601-613.
[http://dx.doi.org/10.17179/excli2020-2932] [PMID: 33883985]
[17]
Osman, S.; Raza, A.; Al-Zaidan, L.; Inchakalody, V.P.; Merhi, M.; Prabhu, K.S.; Abdelaziz, N.; Hydrose, S.; Uddin, S.; Dermime, S. Biomed. Pharmacother., 2021, 141, 111844.
[http://dx.doi.org/10.1016/j.biopha.2021.111844] [PMID: 34174504]
[18]
Chakrabarti, R.; Subramaniam, V.; Abdalla, S.; Jothy, S.; Prud’homme, G.J. Anticancer Drugs, 2009, 20(5), 334-345.
[http://dx.doi.org/10.1097/CAD.0b013e328327994e] [PMID: 19322072]
[19]
Shiozaki, A.; Kudou, M.; Ichikawa, D.; Fujiwara, H.; Shimizu, H.; Ishimoto, T.; Arita, T.; Kosuga, T.; Konishi, H.; Komatsu, S.; Okamoto, K.; Marunaka, Y.; Otsuji, E. J. Gastroenterol., 2018, 53(2), 197-207.
[http://dx.doi.org/10.1007/s00535-017-1338-x] [PMID: 28389731]
[20]
Huang, W.; Zhang, L.; Yang, M.; Wu, X.; Wang, X.; Huang, W.; Yuan, L.; Pan, H.; Wang, Y.; Wang, Z.; Wu, Y.; Huang, J.; Liang, H.; Li, S.; Liao, L.; Liu, L.; Guan, J. J. Exp. Clin. Cancer Res., 2021, 40(1), 87.
[http://dx.doi.org/10.1186/s13046-021-01878-x] [PMID: 33648530]
[21]
Suwa, S.; Kasubata, A.; Kato, M.; Iida, M.; Watanabe, K.; Miura, O.; Fukuda, T. Int. J. Oncol., 2015, 46(3), 1369-1376.
[http://dx.doi.org/10.3892/ijo.2015.2825] [PMID: 25572287]
[22]
Ismail, M.M.F.; El-Zahabi, H.S.A.; Ibrahim, R.S.; Mehany, A.B.M. Bioorg. Chem., 2020, 105, 104368.
[http://dx.doi.org/10.1016/j.bioorg.2020.104368] [PMID: 33091671]
[23]
Das, B.; Venkateswarlu, K.; Majhi, A.; Siddaiah, V.; Reddy, K.R. J. Mol. Catal. Chem., 2007, 267(1-2), 30-33.
[http://dx.doi.org/10.1016/j.molcata.2006.11.002]
[24]
Chandrabalan, A.; McPhillie, M.J.; Morice, A.H.; Boa, A.N.; Sadofsky, L.R. Eur. J. Med. Chem., 2019, 170, 141-156.
[http://dx.doi.org/10.1016/j.ejmech.2019.02.074] [PMID: 30878828]
[25]
Mosmann, T. J. Immunol. Methods, 1983, 65(1-2), 55-63.
[http://dx.doi.org/10.1016/0022-1759(83)90303-4] [PMID: 6606682]
[26]
Klejborowska, G.; Urbaniak, A.; Maj, E.; Preto, J.; Moshari, M.; Wietrzyk, J.; Tuszynski, J.A.; Chambers, T.C.; Huczyński, A. Bioorg. Chem., 2020, 97, 103664.
[http://dx.doi.org/10.1016/j.bioorg.2020.103664] [PMID: 32106039]
[27]
Bui, T.H.; Le, T.T.; Vu, T.T.; Hoang, X.T.; Luu, V.C.; Vu, D.H. Bull. Korean Chem. Soc., 2012, 33(5), 1586-1592.
[http://dx.doi.org/10.5012/bkcs.2012.33.5.1586]
[28]
Stiborová, M.; Poljaková, J.; Martínková, E.; Bořek-Dohalská, L.; Eckschlager, T.; Kizek, R.; Frei, E. Interdiscip. Toxicol., 2011, 4(2), 98-105.
[http://dx.doi.org/10.2478/v10102-011-0017-7] [PMID: 21753906]
[29]
Darakhshan, S.; Ghanbari, A. J. Biomed. Sci., 2013, 20(1), 76.
[http://dx.doi.org/10.1186/1423-0127-20-76] [PMID: 24143895]
[30]
Quayle, L.A.; Pereira, M.G.; Scheper, G.; Wiltshire, T.; Peake, R.E.; Hussain, I.; Rea, C.A.; Bates, T.E. Oncotarget, 2017, 8(51), 88670-88688.
[http://dx.doi.org/10.18632/oncotarget.20858] [PMID: 29179466]
[31]
Haque, S.; Morris, J.C. Hum. Vaccin. Immunother., 2017, 13(8), 1741-1750.
[http://dx.doi.org/10.1080/21645515.2017.1327107] [PMID: 28575585]
[32]
Kim, B.G.; Malek, E.; Choi, S.H.; Ignatz-Hoover, J.J.; Driscoll, J.J. J. Hematol. Oncol., 2021, 14(1), 55.
[http://dx.doi.org/10.1186/s13045-021-01053-x] [PMID: 33823905]
[33]
Wang, J.; Xiang, H.; Lu, Y.; Wu, T. Int. J. Mol. Med., 2021, 47(4), 55.
[http://dx.doi.org/10.3892/ijmm.2021.4888] [PMID: 33604683]
[34]
Available from: https://www.rcsb.org/3d sequence/1VJY?assemblyId=1

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy